2194 results about "Chemo therapy" patented technology

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

The invention relates to the technical field of medical data processing and prediction, and discloses a chemotherapy adverse reaction prediction and intervention system based on big data. The system integrates an unstructured disease course text and structured inspection data of a patient, generates a time-series symptom event, and performs time window alignment and fusion on the time-series symptom event, a medication record and a physical sign monitoring stream to form a multi-dimensional time-series data block. The system is combined with an external medical knowledge base to construct a dynamic association network among symptoms, medicines and physiological indexes, and dynamically calculates the confidence coefficient of an adverse reaction mode according to real-time data. By using a predictive model of the timing attention mechanism, the system can output a continuous curve of patient risk over time. The system automatically matches and generates a personalized intervention instruction sequence containing specific measures and execution time windows according to key time points and modes when the risk curve exceeds a threshold value. According to the invention, dynamic and advanced early warning and accurate intervention of adverse reaction risks of chemotherapy are realized.

The invention discloses a group of gene markers for predicting or evaluating neoadjuvant chemotherapy response of breast cancer and application of the gene markers. The gene markers comprise CCNA2, CCND1, CD52, ESR1 and FAM234B. The system for predicting or evaluating the neoadjuvant chemotherapy reaction of the breast cancer is constructed on the basis of the gene marker, and can accurately predict or evaluate whether the breast cancer patient has the risk that complete remission cannot be achieved after neoadjuvant chemotherapy, and discriminate whether the breast cancer patient can benefit from the neoadjuvant chemotherapy reaction; therefore, whether the breast cancer patient can be subjected to neoadjuvant chemotherapy or not is accurately predicted, medical intervention is performed in time, and the method has important clinical reference value.

The invention discloses a longitudinal analysis-based lung cancer chemotherapy combined immunotherapy patient symptom prediction method, which comprises the following steps: S1, collecting a multi-modal medical data set of a patient, and carrying out data preprocessing; S2, carrying out time sequence integration on the preprocessed multi-modal medical data set to construct a longitudinal analysis data set; s3, constructing a symptom weight adaptive modeling method based on an attention mechanism; s4, forming a symptom-treatment causal relationship evaluation model; s5, inputting real-time multi-modal medical data of the patient into the symptom-treatment causal relationship evaluation model, and classifying prediction results; s6, generating an individual symptom risk assessment report of the patient according to a prediction result; s7, the clinician dynamically optimizes the chemotherapy dose, the immunotherapy dose and the drug use time of the patient based on the individualized symptom risk assessment report. The invention provides an effective technical means for accurately optimizing a lung cancer chemotherapy and immunotherapy combined scheme.

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

The invention discloses a tumor disease assessment method based on big data, and particularly relates to the technical field of tumor disease assessment. Medical data and living habit data of a patient are collected through multiple data interfaces, integration is carried out through preprocessing and a multi-modal data fusion technology, tumor microenvironment features and drug metabolism features are extracted, a comprehensive feature vector is generated, the effectiveness of a chemotherapy regimen is predicted by using a machine learning model, and when the effectiveness of the chemotherapy regimen is low, the chemotherapy regimen is identified. Newest clinical tests and drug data are introduced regularly, model parameters are dynamically optimized in combination with the chemotherapy regimen improvement effect, it is ensured that the model reflects the newest clinical progress in real time, the problems of model updating lag and drug innovation mismatching are effectively solved, the accuracy and effectiveness of a treatment regimen are improved, and the treatment cost is reduced. And meanwhile, side effects caused by blind attempts are reduced, and powerful support is provided for personalized precise medical treatment.

The invention provides a composition for promoting hair regeneration after chemotherapy as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: modifying the surface of a gold nanocage with polydopamine, loading the modified gold nanocage on an exosome, complexing magnesium ions and zinc ions to prepare a modified exosome, preparing a nano drug-loaded liposome from curcumin, resveratrol and epigallocatechin gallate, mixing the nano drug-loaded liposome with the modified exosome to prepare a multi-layer liposome, and preparing the multi-layer liposome from the nano drug-loaded liposome. And mixing with a penetration enhancer, and adding into a temperature-sensitive hydrogel system to prepare the composition for promoting hair regeneration after chemotherapy. The composition for promoting hair regeneration after chemotherapy has a good transdermal absorption promoting effect, can slowly release drugs, promotes hair follicles to be converted from a resting stage to a growing stage under the synergistic effect of the drugs, regulates and controls multiple pathways (such as anti-apoptosis, angiogenesis promotion and anti-inflammation) at the same time, is matched with a complex pathological mechanism of hair regeneration after chemotherapy, and can promote hair regeneration after chemotherapy. Wide application prospects are realized.

The invention provides a tumor treatment effect prediction method based on multi-modal data, and relates to the field of medical artificial intelligence. The method comprises the following steps: collecting magnetic resonance image data, histopathological section images and clinical baseline data of a tumor patient and a treatment response evaluation record after neoadjuvant chemotherapy; the collected image information is preprocessed; feature extraction is carried out based on the preprocessed image information; screening a feature subset with the highest prediction value from the extracted features; constructing a radiopathomics fusion model by using the feature subset with the highest prediction value; evaluating the radiopathomics fusion model; and predicting the tumor treatment effect by using the evaluated radiopathomics fusion model. The problems that an existing tumor neoadjuvant chemotherapy (NACT) curative effect prediction method is low in accuracy, poor in generalization ability, lack of multi-modal data fusion and insufficient in model interpretability are solved.

The invention provides a whole-process targeting polypeptide, a drug compound thereof, a drug delivery system and application of the whole-process targeting polypeptide. The whole-process targeting polypeptide comprises pHA and VAP which are covalently connected through a bridging structure; the VAP is LVAP, a reverse sequence polypeptide of the LVAP, DVAP or SVAP; wherein the amino acid sequence of the LVAP is as shown in SEQ ID NO: 1; the SVAP is a D-configuration polypeptide of the LVAP; the DVAP is a D-configuration polypeptide of the LVAP inverted sequence polypeptide; the bridging structure is amino-monoethylene glycol-carboxylic acid or a derivative thereof. The whole-process targeting polypeptide not only can cross a blood-brain barrier, target tumor neovascularization, cross a blood-tumor barrier, target tumor mimicry vessels, tumor cells and stem cells thereof, but also has better tumor cell affinity, anti-tumor treatment and in-vivo safety effects. Meanwhile, the drug compound or the drug delivery system has a synergistic effect after being combined with a chemotherapeutic drug, and the anti-tumor drug effect can be remarkably improved.

The invention relates to the field of multi-modal learning, in particular to a colorectal cancer drug chemotherapy reaction prediction system and a storage medium, and a computer program in the storage medium executes the following steps: constructing a PDO model and a PDOX model based on tumor cells; obtaining a standardized median inhibitory concentration value and a standardized relative tumor proliferation rate of the colorectal cancer patient by utilizing the PDO model and the PDOX model; based on the obtained medical record and pathological examination of the colorectal cancer patient, obtaining the age, ASA score, Ki-67 index, combined positive score and clinical outcome of the patient, and further constructing a sample set in combination with a standardized median inhibitory concentration value and a standardized relative tumor proliferation rate; and constructing a model for predicting the chemotherapy reaction of the colorectal cancer drug on the basis of multi-factor logistic regression, training and evaluating the model by using the sample set, and performing chemotherapy guidance on a to-be-treated colorectal cancer patient. The problems that in the prior art, chemotherapy reaction prediction of the colorectal cancer patient is not accurate enough and low in efficiency are solved.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The application describes the first-in-human study on using a anti-KLK2xCD3 bispecific antibody and another anti-cancer drug, in particular, in particular a taxane chemotherapy or Androgen Receptor Pathway Inhibitor (ARPI), to provide enhanced antitumor efficacy with a deeper and more durable clinical response.

The invention discloses an OTX-015 (Ox-015) loaded cascaded responsive nano particle and a preparation method thereof. The nanoparticle has a three-layer core-shell structure, wherein the innermost layer is a cross-linked nanoparticle of chitosan and paclitaxel; the middle layer is a polydopamine layer loaded with a bromodomain inhibitor OTX-015; the outermost layer is a gelatin layer grafted with babali; wherein the cross-linked substance of the chitosan and the paclitaxel is a cross-linked substance containing a disulfide bond. The invention also provides a preparation method of the cascade responsive nano-particle and application of the cascade responsive nano-particle in preparation of an antitumor drug targeted delivery system. The nanoparticle provided by the invention improves the tumor microenvironment while activating in-vivo autoimmunity, and kills tumor cells by using photothermal therapy assisted chemotherapy drugs, so that the synergistic effect of chemotherapy / photothermal therapy / immunotherapy is realized, and a new idea is provided for clinical tumor treatment.

The invention relates to a breast cancer cardiotoxicity risk prediction system based on multi-modal data fusion. According to the system, multi-source heterogeneous medical data such as electronic health records, dynamic electrocardiogram monitoring, echocardiography video streams, chemotherapy medication time sequence data and pathological section images are collected in real time through a distributed architecture, and the storage efficiency is optimized by adopting a layered compression strategy. According to the system, risk indexes are mapped to a three-dimensional heart thermodynamic diagram, key feature contribution degrees are displayed in an associated manner, and a dynamic risk knowledge map is established to reveal a toxicity generation path. The system deploys an incremental learning mechanism to realize continuous optimization of the model, guarantees data security through differential privacy and federal learning, sets a real-time early warning feedback loop, triggers clinical intervention when the risk exceeds a threshold value, and dynamically adjusts the weight of the model according to the feedback of a physician, thereby remarkably improving the prediction accuracy and clinical applicability.

The invention discloses a breast cancer neoadjuvant chemotherapy curative effect prediction method and system, and relates to the medical image processing and analysis technology, and the method comprises the steps: carrying out the Macenko dyeing normalization of a sample HE pathological image of a patient; extracting a tissue region from the normalized sample HE pathological image by using an HEST method; inputting the extracted tissue region into a Prov-GigaPath network, extracting a feature vector of a specified dimension under set parameters, and performing dimension reduction on the extracted feature vector; inputting the feature vectors subjected to dimension reduction into an ABMIL model, and training the feature vectors; and predicting the HE pathological image of the patient based on the trained ABMIL model, and visualizing the prediction result by using the attention score of the trained ABMIL model. According to the method provided by the invention, multi-level complex features such as cellular morphology and tissue structure in the HE image can be automatically mined, and the accuracy and reliability of prediction are greatly improved.

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

Described herein are compositions, systems, and methods for targeted and controlled drug release. In some embodiments, the compositions, systems, and methods may comprise magnetoelectric silica nanoparticles for targeted and controlled release of chemotherapeutic drugs for cancer treatment. In some embodiments, an external magnetic field may be used to release one or more drugs from the magnetoelectric silica nanoparticles. The disclosed compositions, systems, and methods may improve drug targeting and reduce systemic drug toxicity.

The invention relates to application of a platelet reaction protein 4 in preparation of an alopecia medicine, and belongs to the field of medical biology. The invention aims to solve the technical problems of limited curative effect, obvious side effect and narrow application range of the existing alopecia treatment medicine. The invention provides an application of a platelet reaction protein 4 (THBS4) in preparation of an alopecia medicinal preparation, which can promote hair follicles to be converted from a resting period to a growing period by regulating and controlling a mechanical microenvironment around the hair follicles, enhancing the interaction between fibroblasts and hair follicle stem cells and activating regeneration signal channels in hair papilla and hair bud areas. The traditional Chinese medicine composition breaks through the limitation that existing treatment only aims at specific alopecia types, and can be widely applied to various alopecia diseases such as androgenetic alopecia, pressure alopecia and alopecia after chemotherapy. And compared with the traditional medicine, the traditional Chinese medicine composition has the advantages of quick response, no skin irritation reaction and improved hair follicle regeneration efficiency, and provides a brand new solution for safe and efficient treatment of alopecia.

The invention relates to the technical field of medicines, and provides mitoxantrone-loaded ZIF-8 nanoparticles, a preparation method thereof and an application of the mitoxantrone-loaded ZIF-8 nanoparticles in tumor chemical-immunotherapy. Aiming at the defects of combined chemotherapy and immunotherapy clinically at the present stage, MIT ZIF-8 synthesized by a normal-temperature full-water-phase one-pot method is used as a novel chemical-immunotherapy scheme, and the capability of inducing cell immunogenic death of a chemotherapeutic drug mitoxantrone is enhanced by utilizing pyroptosis; the anti-tumor immune activation capability is enhanced while tumor cells are killed through chemotherapy, effective chemical-immune therapy is achieved, and the responsiveness of tumors to immune checkpoint inhibitor therapy is enhanced.

The invention provides an engineered membrane coated nano drug delivery system and application thereof, and belongs to the technical field of nano biomedices.The drug delivery system comprises an inner core combined with a drug, the inner core is coated with a cell membrane, based on the nano drug loading technology and the membrane coating technology, DOX and SRF are loaded on mPDA mesoporous nanoparticles, and thyroid cancer synergistic killing nanoparticles mPDS are formed; the bionic drug delivery system is characterized in that mPDS is used as a target drug delivery system, mPDS is coated with a genetically engineered tumor cell membrane, a dual-targeting membrane-coated nano drug delivery system (mPDS-coated CAR-M) is obtained, and the bionic drug delivery system can penetrate through thyroid cancer in a targeted manner, gather in a focus and reduce side effects of chemotherapy; when near-infrared irradiation is carried out on local tumor, DOX and SRF in mPDS are released, the synergistic effect of photothermal therapy-chemotherapy-targeted therapy is achieved, and the thyroid cancer is killed synergistically.

The invention provides a screening platform for chemotherapy combined anti-tumor natural products and application of the screening platform. PTC has tumor cells, interstitial cells, fibroblasts and immune cells from primary epithelium, is rich in cell components, and has advantages in the aspect of tumor microenvironment simulation. Meanwhile, PTC can reproduce tumor heterogeneity, the culture success rate and clinical consistency can reach 90% or above, and the detection period is within two weeks. And the detection result can be read through AI intelligent software, so that the accuracy can be further improved. The screening period can be shortened, the cost is reduced, and the accuracy is improved; according to the platform, high-throughput screening can be carried out in a short time, and the treatment effect of a chemotherapy drug combined anti-tumor natural product drug scheme can be predicted.

The invention provides a nano-drug based on atomic layer deposition and a preparation method of the nano-drug, mesoporous silica is taken as a carrier, bimetallic nanoparticles are precisely deposited through ALD, and chemotherapeutic drugs and antibacterial components are loaded by combining amination and targeted PEG modification, so that the following functions are realized: (1) H2O2 in a tumor microenvironment is catalyzed to generate reactive oxygen species (ROS); removing fusobacterium nucleatum and damaging a biological membrane of the fusobacterium nucleatum; (2) GSH is consumed through Fenton reaction, and tumor drug resistance is reversed; and (3) the drug is released in pH response, and tumor cells are accurately killed. The invention further provides application of the nano-drug based on atomic layer deposition in treatment of related drug-resistant colorectal cancer induced by fusobacterium nucleatum, the process is controllable, the biocompatibility is excellent, the treatment effect on the drug-resistant colorectal cancer is remarkably improved, and the nano-drug has wide clinical application prospects.

The invention discloses a multi-mode chemotherapy response prediction system and method. A data set is based on pathological image data and gene data related to chemotherapy data; the first data processing module acquires a histopathological image data block through multi-parameter collaborative acquisition of chemotherapy patient pathological image slice segmentation and hole elimination; the second data processing module queries a gene data set according to gene expression standardization based on chemotherapy patient genes to obtain a first pathological gene feature vector; the third data processing module is used for processing the tissue pathological image data block based on an ImageNet pre-trained ResNet-50 model to obtain a first pathological image feature vector; the bilinear pooling module combines the first pathological gene feature vector and the first pathological image feature vector based on a cross-modal interaction method to obtain a fused pathological image gene feature vector; the attention clustering module performs package-level prediction on the fused pathological image features and gene features based on multi-instance learning to obtain patient chemotherapy response; the method can more accurately and reliably predict the potential response of the patient after chemotherapy.

The invention relates to the technical field of biological medicine, in particular to immunogen cell death enhanced nano-vesicle hydrogel and application thereof. The invention provides a 3D-printable multifunctional synergistic immunogen cell death enhanced nano-vesicle hydrogel, which is characterized in that SerMA hydrogel is used as a matrix, cell membrane nano-vesicles (N (at) ILO) loaded with a photothermal agent IR1061, a chemotherapeutic drug OXA and a tumor acidic microenvironment regulator Lon are encapsulated, initial tumor immunogen cell death is triggered through a photothermal effect, and the tumor immunogen cell death enhanced nano-vesicle hydrogel can be used for 3D printing. OXA further enhances the ICD effect, Lon regulates the acidic tumor microenvironment to improve the T cell activity, and postoperative multi-mode synergistic anti-tumor treatment is achieved; meanwhile, the hydrogel also has excellent photocuring 3D printing capability, can be used for individually constructing a filling structure matched with a postoperative defect area, has a wide application prospect, and provides a new strategy and theoretical basis for postoperative comprehensive treatment of choroidal melanoma.

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

Chemotherapeutic Combinations The present disclosure relates to novel combinations of bifunctional molecules that contain a BRD9 binding ligand with at least one chemotherapeutic agent. The novel combinations are useful in the treatment of cancer.

The invention discloses poplar and phellinus igniarius polysaccharide SVP-1 as well as a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus igniarius polysaccharide SVP-1 provided by the invention has remarkable anti-tumor activity, and can effectively inhibit proliferation, invasion and migration of tumor cells so as to block malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of polysaccharide components are ensured, and a reliable basis is provided for development of antitumor drugs. When the traditional Chinese medicine composition is used together with radiotherapy and chemotherapy medicines, a synergistic effect can be achieved, the sensitivity of tumors to treatment can be improved, the toxic and side effects of radiotherapy and chemotherapy can be relieved, and the effects of reducing toxicity and increasing efficiency are achieved. According to the combined treatment strategy, the curative effect of the existing tumor therapy can be remarkably improved, meanwhile, adverse reactions are reduced, and a new optimization scheme is provided for clinical tumor treatment.

The invention relates to the technical field of disease curative effect evaluation, and discloses a method for evaluating the curative effect of granulocyte deficiency accompanying fever after hematologic tumor chemotherapy based on machine learning, and the method comprises the steps: S1, collecting and preprocessing multi-center medical data, the data comprising structured clinical data and multi-modal unstructured data; s2, a curative effect prediction model is constructed based on a graph neural network, and a central moment constraint-based graph federal learning training model is adopted, wherein a patient graph is constructed as an original graph and an enhanced graph is generated; respectively processing the original image and the enhanced image through a two-channel image convolutional neural network, and extracting a high-order representation vector; constructing an enhanced perception loss function based on the high-order representation vectors of the original image and the enhanced image; combining a federated learning framework with multi-center data to train a model; and S3, predicting a curative effect evaluation result through the trained curative effect prediction model. The accuracy, the stability and the clinical interpretability of curative effect evaluation are improved.

The invention relates to the technical field of electrocardiosignal detection, in particular to a leukemia child cardiotoxicity prediction system based on electrocardio dynamic evolution characteristics, which comprises the following steps: acquiring electrocardiosignals of a leukemia child in a whole chemotherapy cycle; performing empirical mode decomposition on the preprocessed electrocardiosignal, and performing dynamic modeling on an empirical mode decomposition result to obtain time domain representation and dynamic domain representation under different scales; performing cross-domain fusion on the time domain representation and the dynamic domain representation under different scales to obtain multi-scale dynamic and static characteristics; on the basis of the multi-scale dynamic and static characteristics, electrocardio time-varying dynamic evolution characteristics of the child patient in the whole chemotherapy period are calculated; based on the electrocardio time-varying dynamic evolution characteristics of the whole chemotherapy cycle of the child patient, predicting an early prediction result of cardiotoxicity of the child patient; and explaining the prediction result to obtain the causal relationship between the cardiotoxicity and the electrocardio time-varying dynamic evolution characteristics. And the accuracy of cardiac toxicity prediction is improved.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.